Oxygen drops during eye injections in preterm babies: a hidden risk?

NCT ID NCT07701759

Recruiting now Knowledge-focused Sponsor: Minia University Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at how often oxygen levels drop in premature infants when they receive an eye injection of ranibizumab for retinopathy of prematurity (ROP). Researchers reviewed records from 74 infants treated across multiple hospitals, tracking oxygen saturation during the procedure. The goal is to understand the frequency and severity of hypoxia, which has not been well studied in this setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ranibizumab
What this could lead to: If this study identifies how often and how severely oxygen levels drop during treatment, it could lead to better monitoring and safer procedures for premature infants with ROP.
What could go wrong: This is a small, retrospective observational study, so it can show patterns but cannot prove cause and effect. Results may not apply to all hospitals or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINOPATHY OF PREMATURITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

QUMC
RECRUITING

Buraidah, Saudi Arabia

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.